Related Experiment Video
Updated: Sep 15, 2025

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
Published on: January 20, 2023
Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market
Luis Padrela1, Rabah Mouras2, Donal Killackey3
1SSPC, The Research Ireland Centre for Pharmaceuticals, Limerick, Ireland; Department of Chemical Sciences, Bernal Institute, University of Limerick, Limerick, Ireland.
None:
It is a major challenge to produce proof-of-concept (PoC) pharmaceutical nanoformulations of the required quality level, and in sufficient quantities for late preclinical and clinical testing. The creation of bespoke capabilities to assist in the translation of early stage PoC medicines could greatly reduce time and cost to bring new and innovative therapies to the market. This paper reflects on current barriers hampering the commercialization of novel nanopharmaceuticals and discusses the potential for integrated approaches to bring together existing and new processing infrastructures to de-risk and accelerate the development, manufacturing and market entry of the next-generation nanopharmaceuticals.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
Drug Discovery: Overview
Preclinical Development: Overview

